Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference
11 2월 2025 - 10:55PM
Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines
company committed to developing curative therapeutics for patients
using its proprietary gene editing toolbox, today announced that
Brian C. Thomas, PhD, CEO and founder of Metagenomi, will
participate in a fireside chat at TD Cowen's 45th Annual Health
Care Conference on Wednesday, March 5, 2025, from 1:10-1:40 p.m. ET
in Boston. The company will host one-on-one investor meetings at
the conference.
A live webcast will be available in the investor section of the
company's website at https://ir.metagenomi.co/ and a replay will be
available for a limited time at the same address.
About Metagenomi
Metagenomi is a precision genetic medicines company committed to
developing curative therapeutics for patients using its AI-driven
metagenomics platform. Metagenomi is harnessing the power of
metagenomics, the study of genetic material recovered from the
natural environment, to unlock four billion years of microbial
evolution to discover and develop a suite of novel editing tools
capable of correcting any type of genetic mutation found anywhere
in the genome. Its comprehensive genome editing toolbox includes
programmable nucleases, base editors, and RNA and DNA-mediated
integration systems (including prime editing systems and clustered
regularly interspaced short palindromic repeat associated
transposases (CAST)). Metagenomi believes its proprietary, modular
toolbox positions the company to access the entire genome and
select the optimal tool to unlock the full potential of genome
editing for patients. For more information, please visit
https://metagenomi.co.
Cautionary Note Regarding Forward‐Looking
Statements
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, each as
amended. Such statements, which are often indicated by terms such
as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “will,” “would”
and similar expressions, include, but are not limited to, any
statements relating to our growth strategy and product development
programs, including the timing of and our ability to conduct
IND-enabling studies, make regulatory filings such as INDs,
statements concerning the potential of therapies and product
candidates, and any other statements that are not historical facts.
Forward-looking statements are based on management’s current
expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial
condition, and stock value. Factors that could cause actual results
to differ materially from those currently anticipated include:
risks relating to our growth strategy; our ability to obtain,
perform under, and maintain financing and strategic agreements and
relationships; risks relating to the results of research and
development activities; risks relating to the timing of starting
and completing clinical trials; uncertainties relating to
preclinical and clinical testing; our dependence on third party
suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need
for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks
described in “Risk Factors,” in our most recent Form 10-K and our
most recent 10-Qs on file with the Securities and Exchange
Commission. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as required by law,
and we claim the protection of the safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform
Act of 1995.
Contact:
IR@metagenomi.co
Metagenomi (NASDAQ:MGX)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Metagenomi (NASDAQ:MGX)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025